ManNAc

DRUG4 trials

Sponsors

National Human Genome Research Institute (NHGRI), Leadiant Biosciences, Inc.

Conditions

Focal Segmental GlomerulosclerosisGNE MyopathyHereditary Inclusion Body Myopathy (HIBM)

Phase 1

Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)

CompletedNCT01634750

National Human Genome Research Institute (NHGRI)GNE Myopathy, Hereditary Inclusion Body Myopathy (HIBM)

Start: 2012-09-11End: 2013-05-29Updated: 2017-10-19

Phase 2

An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy

CompletedNCT02346461

National Human Genome Research Institute (NHGRI)GNE Myopathy

Start: 2015-02-05End: 2018-11-15Updated: 2019-04-16

Multi-Center Study of ManNAc for GNE Myopathy

Active, not recruitingNCT04231266

Leadiant Biosciences, Inc.GNE Myopathy

Start: 2022-04-05End: 2025-10-30Updated: 2025-06-13

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases

RecruitingNCT06664814

National Human Genome Research Institute (NHGRI)Focal Segmental Glomerulosclerosis

Start: 2026-09-22End: 2030-12-01Target: 30Updated: 2026-09-17

Related Papers

Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study.

2021-07-1336 citations

Population Pharmacokinetic Model of N-acetylmannosamine (ManNAc) and N-acetylneuraminic acid (Neu5Ac) in Subjects with GNE Myopathy.

2021-04-2410 citations

Open-Label Phase 2 Clinical Trial of ManNAc for GNE Myopathy (S23.008)

Neurology2019-04-092 citations

ManNAc Is Safe and Increases Sialic Acid Production in GNE Myopathy (P7.061)

Neurology2015-04-06